(Giloralimab)Biosimilar Reference Antibody-GS40301 新品

货号：GS40301

Giloralimab (development code ABBV-927) is an investigational, potent anti-CD40 agonistic monoclonal antibody being developed for cancer immunotherapy. It functions as a co-stimulatory immune activator. By binding with high affinity to the CD40 receptor (also known as TNFRSF5) expressed on antigen-presenting cells (APCs) such as dendritic cells, B cells, and macrophages, giloralimab mimics the action of its natural ligand, CD40L (CD154). This binding triggers receptor clustering and activation, delivering a powerful activating signal. This signal promotes dendritic cell maturation, enhances antigen presentation, upregulates co-stimulatory molecules (like B7), and licenses APCs to more effectively prime and activate tumor-specific T cells, thereby boosting the anti-tumor immune response.